Fate Therapeutics, Inc.

NasdaqGM FATE

Fate Therapeutics, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -1,325.43%

Fate Therapeutics, Inc. EBT Margin is -1,325.43% for the Trailing 12 Months (TTM) ending September 30, 2024, a -712.95% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Fate Therapeutics, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -163.04%, a 61.73% change year over year.
Fate Therapeutics, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -425.99%, a -18.44% change year over year.
Fate Therapeutics, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -359.66%, a 55.61% change year over year.
Fate Therapeutics, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -810.13%, a 10.01% change year over year.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

NasdaqGM: FATE

Fate Therapeutics, Inc.

CEO	Mr. J. Scott Wolchko
IPO Date	Oct. 1, 2013
Location	United States
Headquarters	12278 Scripps Summit Drive
Employees	181
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Key trends

Past 5 years